Autifony Therapeutics announces publication in Nature Communications showing how novel Kv3 modulators with therapeutic potential can bind and enhance Kv3 ion channel function

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)

Autifony to present preclinical data supporting the efficacy of its novel clinical-stage Kv3 modulators to address cellular dysfunction, ataxia, and seizure susceptibility in PME (Progressive Myoclonic Epilepsy, EPM7) at the American Epilepsy Society (AES) Annual Meeting, taking place 2-6 December 2022 in Nashville, Tennessee

Autifony presents key efficacy data for AUT00206 from a first-in-patient safety/PK study in patients with schizophrenia at the Schizophrenia International Research Society annual meeting

Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders